IP in Systems Biology

September 19, 2006 / Radisson SAS Scandinavia Hotel / Copenhagen, Denmark

This international one day conference will examine how to patent treatment methods and diagnostics to protect innovations within personalised medicines. We are facing a paradigm shift in the global life science industry today. Personalised medicines allow biotech and pharmaceutical companies to deliver customised drugs or treatment options that match each individual’s genetic make-up.

It is important to develop an IP strategy focusing on your personalised medicine innovations where genomic relationships are being used to customise a drug for specific target diseases. The key to success is the combination. Narrow claims protect your biotech invention and will successfully exclude your competitors to exploit the claimed genomic relationship in your patents.

We are pleased being able to present the pioneers within personalised drugs such as DeCode Genetics, Sanofi-Aventis, UCB Group, Bird & Bird, Plougmann & Vingtoft sharing their best experiences to protect your personalised medicine innovations in the era of post-genomics.

For further details and registration, please visit the Labinnovator homepage. 

For programme, please visit: http://www.labinnovator.com/IP_BIO_brochure_b.pdf